Living with it: outlook and quality of life
Many carriers go to school, work and live independently. The main threats to quality of life are untreated kidney disease, mislabelled diabetes, and unsupported speech or learning needs.
The honest summary: outcomes are good for most people, and the outcome is much more about whether the treatable parts are picked up than about the deletion itself.
- Kidney function is normal in the majority; a minority progress to kidney failure, where dialysis and
transplantation are effective options with good reported outcomes.
- Diabetes, when it appears, is manageable - and better managed when correctly labelled as HNF1B-MODY
rather than guessed as type 1 or type 2.
- Speech and learning needs respond well to early, sustained support; adults described in the literature
and by family organisations work, drive, live independently and have families of their own.
- The mental-health piece is the one to keep an eye on into the teens and twenties.
What families consistently report as hardest: not knowing what to expect, being told the deletion "explains everything" (it does not), and having to explain a rare condition to each new clinician. A one-page summary and a link to a family organisation solves a surprising amount of that.
Freshest finding: A source describes a new or expanded observation: “In this report, we describe a 12-year-old Japanese female with early-onset diabetes mellitus, pancreatic hypoplasia, and multiple renal cysts, harboring a novel de novo HNF1B missense variant (p.Met160Thr) located within the POU-specific domain.”
What shapes outcomes
| Factor | Effect |
|---|---|
| Access to surveillance | Earlier detection of CKD/diabetes, before symptoms |
| Correct diabetes label | Changes treatment and family testing |
| Early speech/developmental support | Directly improves communication and school trajectory |
| Mental-health attention in adolescence | Earlier treatment of psychosis/anxiety |
| Accurate recurrence counselling | Better-informed family planning |
| Documentation carried by the family | Avoids repeated testing and uninformed advice |
Long-term medical risks to keep on the radar
- Progressive chronic kidney disease (a minority), hypertension, gout/hyperuricaemia, hypomagnesaemia.
- Diabetes and its complications; pancreatic exocrine insufficiency.
- Persistent speech/language and learning needs; secondary anxiety or low self-esteem.
- Psychiatric illness in early adulthood.
Community perspective
Family organisations (17q12.org, RareChromo/Unique, NORD, Simons Searchlight) report that the most valuable things for families are: a named clinician who understands the condition, a written surveillance plan, and contact with other families. The crawler tracks those organisations so their updates appear in the corpus.
Latest evidence in the collected corpus
New observation reported: In this report, we describe a 12-year-old Japanese female with early-onset diabetes mellitus, pancreatic hypop…
A source describes a new or expanded observation: “In this report, we describe a 12-year-old Japanese female with early-onset diabetes mellitus, pancreatic hypoplasia, and multiple renal cysts, harboring a novel de novo HNF1B missense variant (p.Met160Thr) located within the POU-specific domain.”
“In this report, we describe a 12-year-old Japanese female with early-onset diabetes mellitus, pancreatic hypoplasia, and multiple renal cysts, harboring a novel de novo HNF1B missense variant (p.Met160Thr) located within the POU-specific domain.”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: We report a novel in-frame deletion of HNF1B in a family with renal cysts and MODY, furthering our understandi…
A source describes a new or expanded observation: “We report a novel in-frame deletion of HNF1B in a family with renal cysts and MODY, furthering our understanding of HNF1B -related phenotypes.”
“We report a novel in-frame deletion of HNF1B in a family with renal cysts and MODY, furthering our understanding of HNF1B -related phenotypes.”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: Here, we report a novel in-frame deletion of HNF1B in a family with renal cysts and MODY, furthering our under…
A source describes a new or expanded observation: “Here, we report a novel in-frame deletion of HNF1B in a family with renal cysts and MODY, furthering our understanding of HNF1B -related phenotypes.”
“Here, we report a novel in-frame deletion of HNF1B in a family with renal cysts and MODY, furthering our understanding of HNF1B -related phenotypes.”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: In conclusion, here we report a novel model of non-small cell lung cancer driven by a mutation in Kras and del…
A source describes a new or expanded observation: “In conclusion, here we report a novel model of non-small cell lung cancer driven by a mutation in Kras and deletion of Mst1/2 kinases.”
“In conclusion, here we report a novel model of non-small cell lung cancer driven by a mutation in Kras and deletion of Mst1/2 kinases.”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: Here, we report a novel case of a syndromic HNF1B -deficient paediatric patient that developed HCC with unique…
A source describes a new or expanded observation: “Here, we report a novel case of a syndromic HNF1B -deficient paediatric patient that developed HCC with unique histopathological features characterised by neoplastic syncytial giant cells, which was observed only in one additional case of paediatric cholestatic liver disease of unknown origin.”
“Here, we report a novel case of a syndromic HNF1B -deficient paediatric patient that developed HCC with unique histopathological features characterised by neoplastic syncytial giant cells, which was observed only in one additional case of paediatric…”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: The current study describes the first case of MODY 5 treated with the GLP-1RA, liraglutide, which exerted prot…
A source describes a new or expanded observation: “The current study describes the first case of MODY 5 treated with the GLP-1RA, liraglutide, which exerted protective effects against pancreatic beta cell dysfunction. [ 11 , 12 ] 2 Case report A 17-year-old woman with a 3-month history of thirst, polydipsia, and polyuria underwent urine glucose scre”
“The current study describes the first case of MODY 5 treated with the GLP-1RA, liraglutide, which exerted protective effects against pancreatic beta cell dysfunction. [ 11 , 12 ] 2 Case report A 17-year-old woman with a 3-month history of thirst, polydipsia,…”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: Here, we described five new patients in four families with dup3q29 ranging from 232 to 486 kb in size; based o…
A source describes a new or expanded observation: “Here, we described five new patients in four families with dup3q29 ranging from 232 to 486 kb in size; based on the analysis of our own results and published data, we delineated for the first time the smallest MOR, including only the BDH1 gene, and compared the phenotypes of carriers of reciprocal m”
“Here, we described five new patients in four families with dup3q29 ranging from 232 to 486 kb in size; based on the analysis of our own results and published data, we delineated for the first time the smallest MOR, including only the BDH1 gene, and compared…”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: We reported for the first time three patients with cardiac and great artery malformations…
A source describes a new or expanded observation: “We reported for the first time three patients with cardiac and great artery malformations.”
“We reported for the first time three patients with cardiac and great artery malformations.”corroboration 1 · confidence 97% · updated 2026-11-14 · source
This entry is version 15. The analytical engine only appends the clearly-labelled “Latest evidence” section; the text above is curated and is not rewritten by the machine. Confidence 72% · last updated 2026-11-14 16:44